article · Particle and Fibre Toxicology
This study presents initial evidence that exposure to polystyrene nanoplastics (PS-NPs) can cause cognitive impairment in mice. The research indicates that PS-NPs induce neuronal cuproptosis, a form of cell death, through a mechanism involving oxidative stress and the activation of the ERK-MAPK signalling pathway. These findings offer insights into the potential biological processes underlying the neurotoxic effects of PS-NPs. The work also highlights possible therapeutic targets, such as copper chelation or inhibition of the MAPK pathway, which could help reduce the neurological risks associated with nanoplastic exposure. Further validation in human-relevant models is necessary.
Understanding how nanoplastics affect brain function is crucial given their widespread presence in the environment. This research sheds light on specific cellular mechanisms, such as neuronal cuproptosis, that contribute to cognitive decline. Identifying these pathways could inform strategies to protect neurological health from environmental nanoplastic exposure.
This early-stage research identifies specific biological pathways and molecular targets, such as copper chelation and MAPK inhibition, that could be explored for therapeutic development. Pharmaceutical companies or biotechnology firms might use these insights to develop interventions aimed at mitigating the neurological impacts of nanoplastic exposure. However, these findings require extensive further validation in human-relevant models before any clinical application.
AI-generated from the published abstract. Always read the original work before citing.
This study presents preliminary evidence indicating that PS-NPs may induce neuronal cuproptosis, potentially through the oxidative stress-mediated activation of the ERK-MAPK pathway, which contributes to cognitive dysfunction in mice. These findings provide insights into the potential mechanisms underlying PS-NPs neurotoxicity and highlight possible therapeutic targets, such as copper chelation or MAPK inhibition, for mitigating the neurological risks associated with nanoplastic exposure, pending further validation in human-relevant models.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s12989-025-00633-w
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
